REPORT ID 8198

EMEA (Europe, Middle East and Africa) Cancer Vaccines Market Report 2017

Publish Date
7-Nov-17
Pages
112
Format
Electronic (PDF)

In this report, the EMEA Cancer Vaccines market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Units), revenue (Million USD), market share and growth rate of Cancer Vaccines for these regions, from 2012 to 2022 (forecast)
    Europe: Germany, France, UK, Russia, Italy and Benelux;
    Middle East: Saudi Arabia, Israel, UAE and Iran;
    Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Cancer Vaccines market competition by top manufacturers/players, with Cancer Vaccines sales volume (K Units), price (USD/Unit), revenue (Million USD) and market share for each manufacturer/player; the top players including
    Dendreon
    GlaxoSmithKline
    Merck
    Sanofi
    Amgen
    Biothera
    Isa Pharmaceuticals
    Bristol-Myers Squibb
    Bavarian Nordic
    Antigen Express
    Juvaris Biotherapeutics
    Provectus Biopharmaceuticals
    Aduro BioTech
    Galena Biopharma
    Northwest Biotherapeutics
    Oxford BioMedica
    Inovio Pharmaceuticals
    Vaxon Biotech
    Celldex Therapeutics
    Prima BioMed

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
    Rophylactic Vaccines
    Therapeutic Vaccines

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Adults
    Children

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

EMEA (Europe, Middle East and Africa) Cancer Vaccines Market Report 2017
1 Cancer Vaccines Overview
    1.1 Product Overview and Scope of Cancer Vaccines
    1.2 Classification of Cancer Vaccines
        1.2.1 EMEA Cancer Vaccines Market Size (Sales) Comparison by Type (2012-2022)
        1.2.2 EMEA Cancer Vaccines Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 Rophylactic Vaccines
        1.2.4 Therapeutic Vaccines
    1.3 EMEA Cancer Vaccines Market by Application/End Users
        1.3.1 EMEA Cancer Vaccines Sales (Volume) and Market Share Comparison by Application (2012-2022
        1.3.2 Adults
        1.3.3 Children
    1.4 EMEA Cancer Vaccines Market by Region
        1.4.1 EMEA Cancer Vaccines Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 Europe Status and Prospect (2012-2022)
        1.4.3 Middle East Status and Prospect (2012-2022)
        1.4.4 Africa Status and Prospect (2012-2022)
    1.5 EMEA Market Size (Value and Volume) of Cancer Vaccines (2012-2022)
        1.5.1 EMEA Cancer Vaccines Sales and Growth Rate (2012-2022)
        1.5.2 EMEA Cancer Vaccines Revenue and Growth Rate (2012-2022)

2 EMEA Cancer Vaccines Competition by Manufacturers/Players/Suppliers, Region, Type and Application
    2.1 EMEA Cancer Vaccines Market Competition by Players/Manufacturers
        2.1.1 EMEA Cancer Vaccines Sales Volume and Market Share of Major Players (2012-2017)
        2.1.2 EMEA Cancer Vaccines Revenue and Share by Players (2012-2017)
        2.1.3 EMEA Cancer Vaccines Sale Price by Players (2012-2017)
    2.2 EMEA Cancer Vaccines (Volume and Value) by Type/Product Category
        2.2.1 EMEA Cancer Vaccines Sales and Market Share by Type (2012-2017)
        2.2.2 EMEA Cancer Vaccines Revenue and Market Share by Type (2012-2017)
        2.2.3 EMEA Cancer Vaccines Sale Price by Type (2012-2017)
    2.3 EMEA Cancer Vaccines (Volume) by Application
    2.4 EMEA Cancer Vaccines (Volume and Value) by Region
        2.4.1 EMEA Cancer Vaccines Sales and Market Share by Region (2012-2017)
        2.4.2 EMEA Cancer Vaccines Revenue and Market Share by Region (2012-2017)
        2.4.3 EMEA Cancer Vaccines Sales Price by Region (2012-2017)

3 Europe Cancer Vaccines (Volume, Value and Sales Price), by Players, Countries, Type and Application
    3.1 Europe Cancer Vaccines Sales and Value (2012-2017)
        3.1.1 Europe Cancer Vaccines Sales Volume and Growth Rate (2012-2017)
        3.1.2 Europe Cancer Vaccines Revenue and Growth Rate (2012-2017)
    3.2 Europe Cancer Vaccines Sales and Market Share by Type
    3.3 Europe Cancer Vaccines Sales and Market Share by Application
    3.4 Europe Cancer Vaccines Sales Volume and Value (Revenue) by Countries
        3.4.1 Europe Cancer Vaccines Sales Volume by Countries (2012-2017)
        3.4.2 Europe Cancer Vaccines Revenue by Countries (2012-2017)
        3.4.3 Germany Cancer Vaccines Sales and Growth Rate (2012-2017)
        3.4.4 France Cancer Vaccines Sales and Growth Rate (2012-2017)
        3.4.5 UK Cancer Vaccines Sales and Growth Rate (2012-2017)
        3.4.6 Russia Cancer Vaccines Sales and Growth Rate (2012-2017)
        3.4.7 Italy Cancer Vaccines Sales and Growth Rate (2012-2017)
        3.4.8 Benelux Cancer Vaccines Sales and Growth Rate (2012-2017)

4 Middle East Cancer Vaccines (Volume, Value and Sales Price), by Region, Type and Application
    4.1 Middle East Cancer Vaccines Sales and Value (2012-2017)
        4.1.1 Middle East Cancer Vaccines Sales Volume and Growth Rate (2012-2017)
        4.1.2 Middle East Cancer Vaccines Revenue and Growth Rate (2012-2017)
    4.2 Middle East Cancer Vaccines Sales and Market Share by Type
    4.3 Middle East Cancer Vaccines Sales and Market Share by Application
    4.4 Middle East Cancer Vaccines Sales Volume and Value (Revenue) by Countries
        4.4.1 Middle East Cancer Vaccines Sales Volume by Countries (2012-2017)
        4.4.2 Middle East Cancer Vaccines Revenue by Countries (2012-2017)
        4.4.3 Saudi Arabia Cancer Vaccines Sales and Growth Rate (2012-2017)
        4.4.4 Israel Cancer Vaccines Sales and Growth Rate (2012-2017)
        4.4.5 UAE Cancer Vaccines Sales and Growth Rate (2012-2017)
        4.4.6 Iran Cancer Vaccines Sales and Growth Rate (2012-2017)

5 Africa Cancer Vaccines (Volume, Value and Sales Price) by Players, Countries, Type and Application
    5.1 Africa Cancer Vaccines Sales and Value (2012-2017)
        5.1.1 Africa Cancer Vaccines Sales Volume and Growth Rate (2012-2017)
        5.1.2 Africa Cancer Vaccines Revenue and Growth Rate (2012-2017)
    5.2 Africa Cancer Vaccines Sales and Market Share by Type
    5.3 Africa Cancer Vaccines Sales and Market Share by Application
    5.4 Africa Cancer Vaccines Sales Volume and Value (Revenue) by Countries
        5.4.1 Africa Cancer Vaccines Sales Volume by Countries (2012-2017)
        5.4.2 Africa Cancer Vaccines Revenue by Countries (2012-2017)
        5.4.3 South Africa Cancer Vaccines Sales and Growth Rate (2012-2017)
        5.4.4 Nigeria Cancer Vaccines Sales and Growth Rate (2012-2017)
        5.4.5 Egypt Cancer Vaccines Sales and Growth Rate (2012-2017)
        5.4.6 Algeria Cancer Vaccines Sales and Growth Rate (2012-2017)

6 EMEA Cancer Vaccines Manufacturers/Players Profiles and Sales Data
    6.1 Dendreon
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Cancer Vaccines Product Type, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Dendreon Cancer Vaccines Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 GlaxoSmithKline
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 Cancer Vaccines Product Type, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 GlaxoSmithKline Cancer Vaccines Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Merck
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 Cancer Vaccines Product Type, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Merck Cancer Vaccines Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Sanofi
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 Cancer Vaccines Product Type, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Sanofi Cancer Vaccines Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Amgen
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 Cancer Vaccines Product Type, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Amgen Cancer Vaccines Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Biothera
        6.6.1 Company Basic Information, Manufacturing Base and Competitors
        6.6.2 Cancer Vaccines Product Type, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Biothera Cancer Vaccines Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Isa Pharmaceuticals
        6.7.1 Company Basic Information, Manufacturing Base and Competitors
        6.7.2 Cancer Vaccines Product Type, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Isa Pharmaceuticals Cancer Vaccines Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Bristol-Myers Squibb
        6.8.1 Company Basic Information, Manufacturing Base and Competitors
        6.8.2 Cancer Vaccines Product Type, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Bristol-Myers Squibb Cancer Vaccines Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 Bavarian Nordic
        6.9.1 Company Basic Information, Manufacturing Base and Competitors
        6.9.2 Cancer Vaccines Product Type, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Bavarian Nordic Cancer Vaccines Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 Antigen Express
        6.10.1 Company Basic Information, Manufacturing Base and Competitors
        6.10.2 Cancer Vaccines Product Type, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Antigen Express Cancer Vaccines Sales, Revenue, Price and Gross Margin (2012-2017)
        6.10.4 Main Business/Business Overview
    6.11 Juvaris Biotherapeutics
    6.12 Provectus Biopharmaceuticals
    6.13 Aduro BioTech
    6.14 Galena Biopharma
    6.15 Northwest Biotherapeutics
    6.16 Oxford BioMedica
    6.17 Inovio Pharmaceuticals
    6.18 Vaxon Biotech
    6.19 Celldex Therapeutics
    6.20 Prima BioMed

7 Cancer Vaccines Manufacturing Cost Analysis
    7.1 Cancer Vaccines Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Cancer Vaccines

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Cancer Vaccines Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Cancer Vaccines Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 EMEA Cancer Vaccines Market Forecast (2017-2022)
    11.1 EMEA Cancer Vaccines Sales, Revenue and Price Forecast (2017-2022)
        11.1.1 EMEA Cancer Vaccines Sales and Growth Rate Forecast (2017-2022)
        11.1.2 EMEA Cancer Vaccines Revenue and Growth Rate Forecast (2017-2022)
        11.1.3 EMEA Cancer Vaccines Price and Trend Forecast (2017-2022)
    11.2 EMEA Cancer Vaccines Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.3 Europe Cancer Vaccines Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.4 Middle Eastt Cancer Vaccines Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.5 Africa Cancer Vaccines Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.6 EMEA Cancer Vaccines Sales Forecast by Type (2017-2022)
    11.7 EMEA Cancer Vaccines Sales Forecast by Application (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer